← All stocks

Spero Therapeutics, Inc.

SPRO No buying or selling

CIK 0001701108 #4540 in the set updated 22 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

$0.00

$0.00 against sales at will

By person

12 insiders · 0 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Shukla Sath

CEO & President

—

1,736,883

$4.36M

+52.3%

Rajavelu Esther

See Remarks

—

986,851

$2.48M

+135.0%

Keutzer Timothy

Chief Operating Officer

—

742,506

$1.86M

+39.6%

Mahadevia Ankit

Director

—

703,294

$1.77M

−7.3%

Zack Debra

Chief Medical Officer

—

162,311

$407.40K

—

Deshpande Milind

Director

—

101,454

$254.65K

+42.0%

Tregoning Kathleen

Director

—

85,000

$213.35K

+54.5%

Smith Cynthia

Director

—

85,000

$213.35K

+54.5%

THOMAS FRANK E

Director

—

85,000

$213.35K

+54.5%

Jackson Scott Thomas

Director

—

85,000

$213.35K

+54.5%

VINK PATRICK V.J.J.

Director

—

85,000

$213.35K

+54.5%

Pottage John C Jr

Director

—

85,000

$213.35K

+54.5%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 0

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 0

History held since 7 Nov 2017